Oric Pharmaceuticals (ORIC) Competitors $9.93 +0.10 (+1.02%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$9.83 -0.10 (-1.00%) As of 08/14/2025 04:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ORIC vs. APLS, SRRK, MIRM, MOR, NAMS, AMRX, RARE, KYMR, IMVT, and HCMShould you be buying Oric Pharmaceuticals stock or one of its competitors? The main competitors of Oric Pharmaceuticals include Apellis Pharmaceuticals (APLS), Scholar Rock (SRRK), Mirum Pharmaceuticals (MIRM), MorphoSys (MOR), NewAmsterdam Pharma (NAMS), AMNEAL PHARMACEUTICALS (AMRX), Ultragenyx Pharmaceutical (RARE), Kymera Therapeutics (KYMR), Immunovant (IMVT), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. Oric Pharmaceuticals vs. Its Competitors Apellis Pharmaceuticals Scholar Rock Mirum Pharmaceuticals MorphoSys NewAmsterdam Pharma AMNEAL PHARMACEUTICALS Ultragenyx Pharmaceutical Kymera Therapeutics Immunovant HUTCHMED Oric Pharmaceuticals (NASDAQ:ORIC) and Apellis Pharmaceuticals (NASDAQ:APLS) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment. Which has more risk and volatility, ORIC or APLS? Oric Pharmaceuticals has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Comparatively, Apellis Pharmaceuticals has a beta of 0.78, indicating that its share price is 22% less volatile than the S&P 500. Which has higher valuation and earnings, ORIC or APLS? Oric Pharmaceuticals has higher earnings, but lower revenue than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOric PharmaceuticalsN/AN/A-$127.85M-$1.89-5.25Apellis Pharmaceuticals$781.37M4.46-$197.88M-$1.82-15.18 Do analysts prefer ORIC or APLS? Oric Pharmaceuticals presently has a consensus target price of $17.63, indicating a potential upside of 77.49%. Apellis Pharmaceuticals has a consensus target price of $34.12, indicating a potential upside of 23.53%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts clearly believe Oric Pharmaceuticals is more favorable than Apellis Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oric Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00Apellis Pharmaceuticals 0 Sell rating(s) 9 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.58 Does the media favor ORIC or APLS? In the previous week, Oric Pharmaceuticals had 6 more articles in the media than Apellis Pharmaceuticals. MarketBeat recorded 13 mentions for Oric Pharmaceuticals and 7 mentions for Apellis Pharmaceuticals. Apellis Pharmaceuticals' average media sentiment score of 0.66 beat Oric Pharmaceuticals' score of -0.01 indicating that Apellis Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Apellis Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is ORIC or APLS more profitable? Oric Pharmaceuticals has a net margin of 0.00% compared to Apellis Pharmaceuticals' net margin of -30.24%. Oric Pharmaceuticals' return on equity of -51.75% beat Apellis Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Oric PharmaceuticalsN/A -51.75% -47.09% Apellis Pharmaceuticals -30.24%-116.09%-26.72% Do institutionals and insiders believe in ORIC or APLS? 95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 96.3% of Apellis Pharmaceuticals shares are held by institutional investors. 6.8% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 6.5% of Apellis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryOric Pharmaceuticals beats Apellis Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get Oric Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ORIC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ORIC vs. The Competition Export to ExcelMetricOric PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$954.72M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E Ratio-5.2520.4930.2925.74Price / SalesN/A356.37463.41115.83Price / CashN/A43.0338.2159.48Price / Book2.978.608.826.15Net Income-$127.85M-$54.65M$3.25B$265.06M7 Day Performance7.47%5.86%3.70%2.60%1 Month Performance-9.56%8.86%5.84%2.83%1 Year Performance-8.31%13.33%29.92%25.58% Oric Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ORICOric Pharmaceuticals4.7387 of 5 stars$9.93+1.0%$17.63+77.5%+0.6%$954.72MN/A-5.2580News CoverageEarnings ReportAnalyst ForecastShort Interest ↓APLSApellis Pharmaceuticals4.0083 of 5 stars$23.85-2.1%$34.12+43.1%-23.3%$3.08B$781.37M-13.10770Short Interest ↑SRRKScholar Rock4.481 of 5 stars$31.46-1.5%$45.14+43.5%+250.6%$3.07B$33.19M-10.81140Positive NewsAnalyst RevisionMIRMMirum Pharmaceuticals3.9935 of 5 stars$65.87+9.8%$74.13+12.5%+56.3%$3.01B$336.89M-54.44140Insider TradeHigh Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730NAMSNewAmsterdam Pharma3.5361 of 5 stars$24.37-3.7%$41.20+69.1%+48.1%$2.84B$45.56M-15.044AMRXAMNEAL PHARMACEUTICALS3.0677 of 5 stars$8.84+3.5%$11.60+31.2%+20.2%$2.68B$2.79B884.888,100News CoverageInsider TradeRAREUltragenyx Pharmaceutical4.6669 of 5 stars$27.39-0.5%$81.50+197.6%-44.0%$2.65B$560.23M-4.951,294KYMRKymera Therapeutics2.796 of 5 stars$37.68-7.2%$59.11+56.9%-2.3%$2.65B$47.07M-12.15170News CoverageEarnings ReportAnalyst RevisionHigh Trading VolumeIMVTImmunovant2.899 of 5 stars$14.76-4.5%$35.33+139.4%-49.6%$2.64BN/A-5.39120News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionHCMHUTCHMED2.6473 of 5 stars$15.48+3.2%$28.00+80.9%-17.0%$2.62B$630.20M0.001,811Positive News Related Companies and Tools Related Companies Apellis Pharmaceuticals Competitors Scholar Rock Competitors Mirum Pharmaceuticals Competitors MorphoSys Competitors NewAmsterdam Pharma Competitors AMNEAL PHARMACEUTICALS Competitors Ultragenyx Pharmaceutical Competitors Kymera Therapeutics Competitors Immunovant Competitors HUTCHMED Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ORIC) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oric Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oric Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access